Notch-mediated Conversion of Activated T Cells into Stem Cell Memory-like T Cells for Adoptive Immunotherapy

Overview

Journal Nat Commun

Specialty Biology

Date 2017 May 23

PMID 28530241

Citations 58

Authors

Taisuke Kondo

Rimpei Morita

Yuumi Okuzono

Hiroko Nakatsukasa

Takashi Sekiya

Shunsuke Chikuma

Takashi Shichita

Mitsuhiro Kanamori

Masato Kubo

Keiko Koga

Takahiro Miyazaki

Yoshiaki Kassai

Akihiko Yoshimura

Affiliations

Soon will be listed here.

Abstract

Adoptive T-cell immunotherapy is a promising approach to cancer therapy. Stem cell memory T (T) cells have been proposed as a class of long-lived and highly proliferative memory T cells. CD8 T cells can be generated in vitro from naive CD8 T cells via Wnt signalling; however, methods do not yet exist for inducing T cells from activated or memory T cells. Here, we show a strategy for generating T-like cells in vitro (iT cells) from activated CD4 and CD8 T cells in mice and humans by coculturing with stromal cells that express a Notch ligand. iT cells lose PD-1 and CTLA-4 expression, and produce a large number of tumour-specific effector cells after restimulation. This method could therefore be used to generate antigen-specific effector T cells for adoptive immunotherapy.

Citing Articles

Ex vivo expansion and hydrogel-mediated in vivo delivery of tissue-resident memory T cells for immunotherapy.

Li S, Yao Z, Wang H, Ecker J, Omotoso M, Lee J Sci Adv. 2024; 10(50):eadm7928.

PMID: 39671478 PMC: 11641059. DOI: 10.1126/sciadv.adm7928.

Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach.

Bar O, Porgador A, Cooks T J Extracell Biol. 2024; 3(9):e70011.

PMID: 39328262 PMC: 11424882. DOI: 10.1002/jex2.70011.

Stem-like CD8 T cells in cancer.

Steiner C, Denlinger N, Huang X, Yang Y Front Immunol. 2024; 15:1426418.

PMID: 39211052 PMC: 11357971. DOI: 10.3389/fimmu.2024.1426418.

Engineering synthetic agonists for targeted activation of Notch signaling.

Perez D, Antfolk D, Bustos X, Medina E, Chang S, Ramadan A bioRxiv. 2024; .

PMID: 39149362 PMC: 11326249. DOI: 10.1101/2024.08.06.606897.

Metabolic dialogues: regulators of chimeric antigen receptor T cell function in the tumor microenvironment.

Moraly J, Kondo T, Benzaoui M, DuSold J, Talluri S, Pouzolles M Mol Oncol. 2024; 18(7):1695-1718.

PMID: 38922759 PMC: 11223614. DOI: 10.1002/1878-0261.13691.

References

Sekiya T, Kashiwagi I, Yoshida R, Fukaya T, Morita R, Kimura A . Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. Nat Immunol. 2013; 14(3):230-7. DOI: 10.1038/ni.2520. View

Dotto G . Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer. 2009; 9(8):587-95. PMC: 6059364. DOI: 10.1038/nrc2675. View

Barnden M, Allison J, Heath W, Carbone F . Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol. 1998; 76(1):34-40. DOI: 10.1046/j.1440-1711.1998.00709.x. View

Hui-Yuen J, McAllister S, Koganti S, Hill E, Bhaduri-McIntosh S . Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines. J Vis Exp. 2011; (57). PMC: 3308597. DOI: 10.3791/3321. View

Pulko V, Davies J, Martinez C, Lanteri M, Busch M, Diamond M . Human memory T cells with a naive phenotype accumulate with aging and respond to persistent viruses. Nat Immunol. 2016; 17(8):966-75. PMC: 4955715. DOI: 10.1038/ni.3483. View

Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W . Human TH17 cells are long-lived effector memory cells. Sci Transl Med. 2011; 3(104):104ra100. PMC: 3345568. DOI: 10.1126/scitranslmed.3002949. View

Gattinoni L, Ji Y, Restifo N . Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res. 2010; 16(19):4695-701. PMC: 3393131. DOI: 10.1158/1078-0432.CCR-10-0356. View

Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, Konig J . Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. Hum Gene Ther. 2002; 13(7):815-27. DOI: 10.1089/10430340252898993. View

Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D . Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013; 12(1):114-26. DOI: 10.1016/j.stem.2012.11.002. View

10.

Amsen D, Antov A, Flavell R . The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol. 2009; 9(2):116-24. DOI: 10.1038/nri2488. View

11.

Mueller S, Gebhardt T, Carbone F, Heath W . Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 2012; 31:137-61. DOI: 10.1146/annurev-immunol-032712-095954. View

12.

June C . Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007; 117(6):1466-76. PMC: 1878537. DOI: 10.1172/JCI32446. View

13.

Backer R, Helbig C, Gentek R, Kent A, Laidlaw B, Dominguez C . A central role for Notch in effector CD8(+) T cell differentiation. Nat Immunol. 2014; 15(12):1143-51. PMC: 4232996. DOI: 10.1038/ni.3027. View

14.

Telford W, Bradford J, Godfrey W, Robey R, Bates S . Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells. 2006; 25(4):1029-36. DOI: 10.1634/stemcells.2006-0567. View

15.

Watanabe M, Moon K, Vacchio M, Hathcock K, Hodes R . Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity. 2014; 40(5):681-91. PMC: 4073799. DOI: 10.1016/j.immuni.2014.04.006. View

16.

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

17.

Klebanoff C, Acquavella N, Yu Z, Restifo N . Therapeutic cancer vaccines: are we there yet?. Immunol Rev. 2011; 239(1):27-44. PMC: 3075547. DOI: 10.1111/j.1600-065X.2010.00979.x. View

18.

Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M . Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016; 76(18):5229-5240. PMC: 5026612. DOI: 10.1158/0008-5472.CAN-15-1798. View

19.

Maecker H, McCoy J, Nussenblatt R . Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012; 12(3):191-200. PMC: 3409649. DOI: 10.1038/nri3158. View

20.

Shinkai Y, Rathbun G, Lam K, Oltz E, Stewart V, Mendelsohn M . RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992; 68(5):855-67. DOI: 10.1016/0092-8674(92)90029-c. View